Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury

Journal of the Chinese Medical Association

Volumn 77, Issue 4, 2014, Pages 169-173

  Huang, Yi Shin ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Arylamine acetyltransferase; Cytochrome P450 2E1; Drug induced liver injury; Genetic variation; Glutathione S transferase; Isoniazid; Toxic hepatitis; Tuberculosis

Indexed keywords

ACYLTRANSFERASE; CYTOCHROME P450 2E1; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; HLA ANTIGEN; ISONIAZID; MANGANESE SUPEROXIDE DISMUTASE; PYRAZINAMIDE; RIFAMPICIN; ARYLAMINE ACETYLTRANSFERASE; NAT2 PROTEIN, HUMAN; SUPEROXIDE DISMUTASE; TUBERCULOSTATIC AGENT;

ANTITUBERCULOSIS DRUG INDUCED LIVER INJURY; CLINICAL FEATURE; ETHNICITY; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; REVIEW; RISK FACTOR; TOXIC HEPATITIS; GENETICS;

ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; DRUG-INDUCED LIVER INJURY; GENETIC VARIATION; GLUTATHIONE TRANSFERASE; HUMANS; SUPEROXIDE DISMUTASE;

EID: 84897571138     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2014.01.010     Document Type: Review

References (23)

1. Antituberculosis agents. Clinical and research information on drug-induced liver injury. Available at:. [accessed 12.10.13]. http://livertox.nlm.nih.gov/AntituberculosisAgents.htm.
2. Huang Y.S. Genetic polymorphisms of drug-metabolising enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin Drug Metab Toxicol 2007, 3:1-8.
3. Huang Y.S., Chern H.D., Su W.J., Wu J.C., Lai S.L., Yang S.Y., et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor of antituberculosis drug-induced hepatitis. Hepatology 2002, 35:883-889.
4. Huang Y.S., Chern H.D., Su W.J., Wu J.C., Chang S.C., Chiang C.H., et al. Cytochrome P450 2E1 genetic polymorphism and the susceptibility to anti-tuberculosis drug-induced hepatitis. Hepatology 2003, 37:924-930.
5. Mitchell J.R., Thorgeirsson U.P., Black M., Timbrell J.A., Snodgrass W.R., Potter W.Z., et al. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites. Clin Pharmacol Ther 1975, 18:70-79.
6. Wang J.Y., Liu C.H., Hu F.C., Chang H.C., Liu J.L., Chen J.M., et al. Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect 2011, 62:448-455.
7. Lee S.W., Chung L.S., Huang H.H., Chuang T.Y., Liou Y.H. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 2010, 14:622-626.
8. An H.R., Wu X.Q., Wang Z.Y., Zhang J.X., Liang Y. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol 2012, 39:535-543.
9. Leiro-Fernandez V., Valverde D., Vázquez-Gallardo R., Botana-Rial M., Constenla L., Agúndez J.A., et al. N-Acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. Int J Tuberc Lung Dis 2011, 15:1403-1408.
10. Cai Y., Yi J.Y., Zhou C.H., Shen X.Z. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PLoS ONE 2012, 7:e47769.
11. Wang P.Y., Xie S.Y., Hao Q., Zhang C., Jiang B.F. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2012, 16:589-595.
12. Deng R., Yang T., Wang Y., Tang N. CYP2E1 RsaI/PstI polymorphism and risk of anti-tuberculosis T, drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2012, 16:1574-1581.
13. Vuilleumier N., Rossier M.F., Chiappe A., Degoumois F., Dayer P., Mermillod B., et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006, 62:423-429.
14. Roy B., Ghosh S.K., Sutradhar D. Predisposition of antituberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and haplotype in pediatric patients. J Gastroenterol Hepatol 2006, 21:784-786.
15. Huang Y.S., Su W.J., Huang Y.H., Chen C.Y., Chang F.Y., Lin H.C., et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H: quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007, 47:128-134.
16. Roy B., Chowdhury A., Kundu S. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol 2001, 16:1033-1037.
17. Leiro V., Fernández-Villar A., Valverde D., Constenla L., Vázquez R., Piñeiro L., et al. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int 2008, 28:835-839.
18. Tang N., Deng R., Wang Y., Lin M., Li H., Qiu Y., et al. GSTM1 and GSTT1 null polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2013, 17:17-25.
19. Chang J.C., Liu E.H., Lee C.N., Lin Y.C., Yu M.C., Bai K.J., et al. UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications. Int J Tuberc Lung Dis 2012, 16:376-378.
20. Nanashima K., Mawatari T., Tahara N., Higuchi N., Nakaura A., Inamine T., et al. Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients. Tuberculosis 2012, 92:253-259.
21. Sharma S.K., Balamurugan A., Saha P.K., Pandey R.M., Mehra N.K. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002, 166:916-919.
22. Kim S.H., Kim S.H., Yoon H.J., Shin D.H., Park S.S., Kim Y.S., et al. TNF-α genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis. Liver Int 2012, 32:809-814.
23. Huang Y.S. Tailored drug therapy for mitigating drug-induced liver injury: is this the era of genetic screening?. Pers Med 2010, 7:5-8.